Sections

Colon Cancer

Workup

Approach Considerations

Because early-stage colon cancer is typically asymptomatic, screening plays a major role in the diagnosis of curable cancerous lesions, as well as the detection of precancerous lesions (adenomatous colon polyps). The decline in colorectal cancer incidence and death rates over recent decades has largely been attributed to widespread adoption of screening.^[24]

Screening guidelines endorse the use of several tests and procedures that either detect adenomatous polyps and cancer or that primarily detect cancer. However, guidelines from the American College of Gastroenterology recommend colonoscopy every 10 years, beginning at age 50 years, as the preferred screening strategy.^[46]

A suspicion of colorectal cancer diagnosis warrants rectal examination and colonoscopy with a biopsy of any suspicious lesions. The National Comprehensive Cancer Network recommends that all patients younger than 70 years of age who are diagnosed with colorectal cancer be tested for hereditary nonpolyposis colon cancer syndrome (HNPCC, Lynch syndrome); patients 70 and older should be tested only if they meet the revised Bethesda guidelines for HNPCC.^[47]

After tissue diagnosis is confirmed, laboratory studies are done with a goal of assessing patients’ organ function (liver, kidneys) in anticipation of diagnostic and therapeutic procedures and also to estimate tumor burden. Adequate imaging of the chest and abdomen should be obtained for staging purposes, ideally preoperatively.

Further workup is driven by the following:

Clinical setting (eg, profuse bleeding and obstruction may require emergency surgery)
Patient functional status and comorbidities
Presenting symptoms

Blood Studies

Laboratory studies are done with a goal of assessing patients’ organ function (liver, kidneys) in anticipation of diagnostic and therapeutic procedures and also to estimate tumor burden. Studies may include the following:

Complete blood cell count
Serum chemistries
Liver function tests
Renal function tests
Serum carcinoembryonic antigen (CEA) level

A baseline CEA level should be obtained preoperatively as it carries prognostic value and when highly elevated may indicate more advanced, disseminated disease. Increased levels of serum CEA have been associated with an adverse prognosis in patients with resectable colorectal cancer; however, this biochemical marker has not as of yet been included in colorectal cancer staging guidelines.^[48]

Imaging Studies

Adequate imaging of the chest and abdomen should be obtained for staging purposes, ideally preoperatively. Abdominal/pelvic computed tomography (CT), contrast ultrasound of the abdomen/liver, and abdominal/pelvic magnetic resonance imaging (MRI) scans are appropriate for imaging the abdomen and liver, for the purpose of staging. Imaging studies may also include a chest radiograph or chest CT scan, and an abdominal barium study to better delineate the primary lesion preoperatively.

Positron emission tomography (PET) scanning is emerging as a very useful modality for staging and assessment of colorectal cancers. The newest addition, a fusion PET-CT scan, allows for detection of metastatic deposits and has the added tissue-based resolution of CT. Of note, some histologies, especially a mucinous signet-ring cell variant of colorectal cancer, may not be well visualized on a PET scan.

For more information, see Imaging in Adenocarcinoma of the Colon.

Screening

The goal of colorectal cancer screening is to decrease mortality through diagnosis and treatment of precancerous lesions (adenomatous colon polyps) and early curable cancerous lesions. The evidence for the importance of early detection and removal of colorectal polyps in preventing development of invasive cancer is mostly indirect but has been corroborated by data from many trials.

In the United States, a joint guideline was developed by the American Cancer Society, US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.^[24]The guideline recommends that screening for colorectal cancer and adenomatous polyps start at age 50 years in asymptomatic men and women. In addition, the guideline lists appropriate screening procedures and their indications and frequency, based on projected individual risks of developing colorectal cancer. However, because of rising rates of colorectal cancer in younger persons, the American Cancer Society currently recommends that screening start at age 45 years in persons at average risk.^[49]

Screening options consist of tests that detect adenomatous polyps and cancer, and tests that primarily detect cancer. Any one of these tests can be used for screening.

Tests that detect adenomatous polyps and cancer, and their recommended frequency, include the following:

Flexible sigmoidoscopy every 5 years
Colonoscopy every 10 years
Double-contrast barium enema every 5 years
Computed tomographic (CT) colonography every 5 years

Tests that primarily detect cancer, and their recommended frequency, include the following:

Annual guaiac-based fecal occult blood test with high test sensitivity for cancer
Annual fecal immunochemical test (FIT) with high test sensitivity for cancer
Stool DNA test with high sensitivity for cancer, interval uncertain

A Cochrane Database review of 14 trials found that flexible sigmoidoscopy is more effective at detecting advanced adenoma and carcinoma than stool-based tests.^[50] However, a Norwegian study determined that while the use of flexible sigmoidoscopy for screening reduced the incidence and mortality of colorectal cancer in men, it had little or no effect in women.^[51]

A study by Wilschut et al found that FIT should be used at higher hemoglobin cutoff levels when colonoscopy capacity is limited. The findings suggest that FIT is more effective in terms of outcome and cost than fecal occult blood testing at all colonoscopy capacity levels.^[52]

A retrospective study in which FIT kits were mailed to patients concluded that this is an effective way to screen for colorectal cancer. In the study, the researchers mailed FIT kits to approximately 670,000 adults aged 50–70 years; 48.2% of those completed the test within 1 year. The patients who responded were mailed kits annually for the next 3 years, with response rates ranging from 75%–86%.^[53]

In the study, which comprised 98,678 persons, 20 552 were randomly assigned to screening and 78,126 to no screening. On median follow-up of 14.8 years, the absolute risks for colorectal cancer in women were 1.86% in the screening group and 2.05% in the control group (hazard ratio [HR] 0.92). In men, the corresponding risks were 1.72% and 2.50%, respectively (HR 0.66). The absolute risks for death from colorectal cancer in women were 0.60% in the screening group and 0.59% in the control group (HR 1.01); in men, the corresponding risks were 0.49% and 0.81%, respectively (HR 0.63).^[51]

Positive results on FIT screening were highest in the first round and declined in subsequent years. Overall, FIT screening identified 80% of patients with colorectal cancer diagnosed within 1 year of testing.^[53]

In a cohort study of 70,124 patients with positive FIT results, Corley et al found that patients who underwent colonoscopy within 9 months showed no increased risk for colorectal cancer or advanced-stage disease, compared with those who had colonoscopy done within a month after the positive FIT result. However, patients who did not have procedures done until 10 months or later were at significantly higher risk for cancer findings.^[54]

Patients on clopidogrel therapy are at significantly higher risk for delayed but not immediate bleeding when they have polyps removed during colonoscopy.^[55]Because interruption of clopidogrel therapy in patients with coronary artery disease increases the risk of serious ischemic events, elective colonoscopy and polypectomy should be delayed in these patients until cessation of clopidogrel therapy is considered safe.^[55]

In 2014, the FDA approved Cologuard, a colorectal cancer screening tool that detects DNA mutations and hemoglobin in stool samples. A positive result should be followed up with colonoscopy. Cologuard is recommended for screening of adults of either sex, aged 50 years or older, who are at average risk for colorectal cancer. It is not a replacement for diagnostic or surveillance colonoscopy for individuals at high risk, and its approval did not change practice guidelines that recommend screening using colonoscopy, sigmoidoscopy, or fecal occult blood testing.^[56]

In 2016, the FDA approved the first blood-based colorectal cancer screening test, Epi proColon. This is a qualitative in vitro assay for detecting methylated Septin9 DNA, which has been associated with the occurrence of colorectal cancer, in plasma obtained from whole-blood specimens. It is indicated for use in average-risk patients who have chosen not to undergo other screening methods, such as colonoscopy or stool-based tests.^[57]

Screening for colorectal cancer should start at an earlier age and be more frequent and more stringent for individuals who carry an increased or high risk of developing colorectal cancer, such as persons with any of the following:

Prior history of polyps
Prior history of colorectal cancer
Family history of colon cancer
History of inflammatory bowel diseases

Those genetically diagnosed or suspected of having hereditary familial syndromes such as hereditary nonpolyposis colon cancer syndrome (HNPCC) or familial adenomatous polyposis (FAP) should be treated as having high risk of developing colon and rectal cancer. These patients should adhere to a more intense surveillance protocol.^[58]For more information, see Familial Adenomatous Polyposis and Hereditary Colorectal Cancer.

A French study found that even in patients with no personal or family history of colorectal polyps or cancer, starting colonoscopy screening at age 45 instead of age 50 can be valuable. In a prospective study that included 6027 consecutive screening colonoscopies, Karsenti et al found that for the 515 patients age 45 to 49 years, the average polyp detection rate was 26% and the average neoplasia detection rate was nearly 4%. By comparison, for the 4438 patients older than 50 years, the average polyp detection rate exceeded 35% and the average neoplasia detection rate exceeded 5%. Both rates were markedly lower in the 1076 study patients age 44 years and younger.^[59]

Noting the rise in colorectal cancer rates in the under-50 population, Dr. Karsenti recommends showing these data to patients 45 years and older, as part of the discussion on colorectal cancer prevention.^[59]

A study by Lasser et al found that in an ethnically diverse patient population, completion of colorectal cancer screening was increased by the use of a patient navigation strategy consisting of an introductory letter from the primary care provider with educational material, followed by telephone calls from a language-concordant navigator. Navigator intervention proved particularly beneficial for patients whose primary language was other than English and for black patients.^[60]

Colonoscopy preparation

Guidelines from the Multi-Society Task Force on Colorectal Cancer include the following recommendations for bowel cleansing before colonoscopy^[61]:

Use of a split-dose bowel cleansing regimen (ie, roughly half of the bowel cleansing dose is given on the day of the procedure) is strongly recommended for elective colonoscopy.
A same-day regimen is an acceptable alternative to split dosing, especially for patients undergoing an afternoon examination.
The second dose of split preparation ideally should begin 4–6 h before the time of colonoscopy, with completion of the last dose at least 2 h before the procedure time.
When a split-dose bowel cleansing regimen is used, diet recommendations can include either low-residue or full liquids until the evening on the day before colonoscopy
Selection of a bowel-cleansing regimen should take into consideration the patient's medical history; medications; and, when available, the adequacy of bowel preparation reported from prior colonoscopies.
A split-dose regimen of 4 L polyethylene glycol–electrolyte lavage solution (PEG-ELS) provides high-quality bowel cleansing. In healthy nonconstipated individuals, a 4-L PEG-ELS formulation produces a bowel-cleansing quality that is not superior to a lower-volume PEG formulation.
The routine use of adjunctive agents for bowel cleansing before colonoscopy (eg, simethicone, flavored electrolyte solutions, prokinetics, spasmolytics, bisacodyl, senna, olive oil, and probioticsis) is not recommended. However, additional bowel purgatives should be considered in patients with risk factors for inadequate preparation (eg, patients with a prior inadequate preparation, history of constipation, use of opioids or other constipating medications, prior colon resection, diabetes mellitus, or spinal cord injury).
Although sodium phosphate (NaP) is effective and well tolerated by most patients, the risk of adverse events makes it unsuitable as a first-line agent. NaP should be avoided in elderly patients and in patients with known or suspected inflammatory bowel disease.
Low-volume preparations or extended time delivery for high-volume preparations are recommended for patients after bariatric surgery.

Capsule colonoscopy

For capsule colonoscopy, the patient swallows a pill camera that acquires images as peristalsis propels it through the gastrointestinal tract. The images are transmitted to a recording device and then converted to a video format for viewing on a computer.

In 2014, the US Food and Drug Administration approved the PillCam COLON 2 Capsule Endoscopy System (Given Imaging Limited, Yoqneam, Israel) for use in patients in whom conventional colonoscopy with adequate preparation was conducted, but a complete evaluation of the colon was not technically possible.^[62]In multicenter trials, capsule colonoscopy has demonstrated a sensitivity of 84-89% for detection of polyps larger than 6 mm.^[63]

American College of Gastroenterology guidelines

American College of Gastroenterology (ACG) guidelines for colorectal cancer screening are as follows^[46]:

Tests that prevent cancer are preferred over those that only detect cancer
The preferred colorectal cancer prevention test is colonoscopy every 10 years, beginning at age 50 years, but at age 45 years in African Americans
For patients who decline colonoscopy or another cancer prevention test, the preferred cancer detection test is FIT, conducted annually

Alternative cancer detection tests recommended in the ACG guidelines are as follows:

Flexible sigmoidoscopy every 5-10 years
CT colonography every 5 years, which replaces double contrast barium enema as the radiographic screening alternative for patients who decline colonoscopy

Alternative cancer detection tests in the ACG guidelines are as follows:

Annual Hemoccult Sensa
Fecal DNA testing every 3 years

For screening purposes, patients with one first-degree relative diagnosed with colorectal cancer or advanced adenoma at age 60 years or older are considered at average risk. For patients with a single first-degree relative diagnosed with colorectal cancer or advanced adenoma before age 60 years, or those with two first-degree relatives with colorectal cancer or advanced adenomas, the guideline recommends colonoscopy every 5 years, beginning at age 40 years or at 10 years younger than the age at diagnosis of the youngest affected relative.^[46]

Postpolypectomy surveillance

A 2020 update of US Multi-Society Task Force on Colorectal Cancer guidelines provides recommendations on postpolypectomy surveillance. Screening colonoscopy findings and recommended scheduling of surveillance colonoscopy are as follows^[64]:

Normal colonoscopy, or < 20 hyperplastic polyps < 10 mm: 10 years
1–2 adenomas < 10 mm: 7–10 years
3–4 adenomas < 10 mm: 3–5 years
5–10 adenomas, adenoma ≥10 mm, or adenoma with villous component or high-grade dysplasia: 3 years
More than 10 adenomas: 1 year, with consideration for genetic testing based on adenoma burden, age, and family history
Piecemeal resection of adenoma ≥20 mm: 6 months, then 1 year later, then 3 years after the second examination
1–2 sessile serrated polyps (SSPs) < 10 mm: 5–10 years
3–4 SSPs < 10 mm or hyperplastic polyp ≥10 mm: 3–5 years
5–10 SSPs, SSP ≥10 mm, SSP with dysplasia, or traditional serrated adenoma: 3 years

Molecular Testing

Treatment of metastatic colorectal cancer is increasingly guided by molecular testing of the tumor. The American Society for Clinical Pathology, the College of American Pathologists (CAP), the Association for Molecular Pathology, and the American Society of Clinical Oncology (ASCO) have issued evidence-based guidelines on colorectal cancer molecular testing.^[65] Among the recommendations are the following:

RAS mutational testing of colorectal carcinoma tissue should be performed for patients who are being considered for anti-EGFR therapy; this analysis must include KRAS and NRAS codons 12, 13 of exon 2; 59, 61 of exon 3; and 117 and 146 of exon 4 ("expanded" or "extended" RAS)
BRAF V600 mutational analysis should be done in conjunction with deficient mismatch repair (dMMR)/microsatellite instability (MSI) testing for prognostic stratification
dMMR/MSI testing must be performed in all colorectal cancers for prognostic stratification and identification of Lynch syndrome patients (BRAF mutation testing is not needed for Lynch syndrome if there is no high MSI (MSI-H) with loss of MLH1)
Molecular marker testing (KRAS, extended RAS, BRAF, and dMMR/MSI) of the primary colorectal carcinoma tissue is acceptable; if metastatic tissue is available, that is also acceptable and is preferable in patients with metastatic disease.
Formalin-fixed, paraffin-embedded tissue is an acceptable specimen; use of other specimens will require additional adequate validation, as would any changes in tissue processing protocols

Staging

The TNM staging system has become the international standard for staging of colorectal cancer. It uses the following three descriptors:

T for primary tumor
N for lymph nodal involvement
M for metastasis

See Tables 1 and 2, below^[66]:

Table 1. TNM Classification for Colon Cancer (Open Table in a new window)

Primary tumor (T)
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ: intraepithelial or intramucosal carcinoma (involvement of lamina propria with no extension through the muscularis mucosa)
T1	Tumor invades submucosa (through the muscularis mucosa but not into the muscularis propria)
T2	Tumor invades muscularis propria
T3	Tumor invades through the muscularis propria into the pericolorectal tissues
T4	Tumor invades the visceral peritoneum or invades or adheres to adjacent organ or structure
T4a	Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum)
T4b	Tumor directly invades or is adherent to other organs or structures
T Suffix	Definition
(m)	Select if synchronous primary tumors are found in a single organ
Definition of Regional lymph nodes (N)
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in 1-3 regional lymph nodes (tumor in lymph nodes measuring ≥0.2 mm) or any number of tumor deposits are present and all identifiable nodes are negative
N1a	Metastasis in 1 regional lymph node
N1b	Metastasis in 2-3 regional lymph nodes
N1c	Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized, pericolic, or perirectal/mesorectal tissues without regional nodal metastasis
N2	Metastasis in 4 or more lymph nodes
N2a	Metastasis in 4-6 regional lymph nodes
N2b	Metastasis in 7 or more regional lymph nodes
N Suffix	Definition
(sn)	Select if regional lymph node metastasis identified by sentinel lymph node biopsy only
(f)	Select if regional lymph node metastasis identified by fine needle aspiration or core needle biopsy
Definition of Distant metastasis (M) The terms pM0 and Mx are not valid categories in the TNM system. Assignment of the M category for clinical classification may be cM0, cM1 or pM1. Any of the categories (cM0, CM1 or pM1) may be used with pathological stage grouping.
M Category	M Criteria
cM0	No distant metastasis by imaging or other studies, no evidence of tumor in distant sites or organs. (This category is not assigned by pathologists.)
cM1	Metastasis to one or more distant sites or organs or peritoneal metastasis is identified
cM1a	Metastasis confined to 1 organ or site is identified without peritoneal metastasis
cM1b	Metastasis to two or more sites or organs is identified without peritoneal metastasis
M1c	Metastasis to the peritoneal surface alone or with other site or organ metastases
pM1	Metastasis to one or more distant sites or organs or peritoneal metastasis is identified and microscopically confirmed
pM1a	Metastasis to one site or organ is identified without peritoneal metastasis and microscopically confirmed
pM1b	Metastasis to two or more sites or organs is identified without peritoneal metastasis and microscopically confirmed.
pM1c	Metastasis to the peritoneal surface is identified alone or with other site or organ metastasis and microscopically confirmed

Table 2. Anatomic stage/prognostic groups (Open Table in a new window)

0	Tis	N0	M0
I	T1	N0	M0
	T2	N0	M0
IIA	T3	N0	M0
IIB	T4a	N0	M0
IIC	T4b	N0	M0
IIIA	T1-T2	N1/N1c	M0
	T1	N2a	M0
IIIB	T3-T4a	N1/N1c	M0
	T2-T3	N2a	M0
	T1-T2	N2b	M0
IIIC	T4a	N2a	M0
	T3-T4a	N2b	M0
	T4b	N1-N2	M0
IVA	Any T	Any N	M1a
IVB IVC	Any T Any T	Any N Any T	M1b M1c

For more information, see Colon Cancer Staging.

Prognostic factors associated with staging

Patient prognosis is a function of the clinical and histopathologic stage of colon cancer at diagnosis. In addition to the well-established significance of standard pathologic features such as depth of bowel wall penetration (T), number of locoregional lymph nodes involved (N), and presence of extra-colonic metastases (M), several other factors have been proved to be of importance. These include number of harvested and processed lymph nodes, histologic grade, and evidence of lymphovascular and perineural invasion.

Features that have been shown to be associated with worse prognosis include the following:

Bowel obstruction at diagnosis
Ulcerative growth pattern
Perforation
Elevated preoperative CEA level

Molecular prognostic factors that have been investigated but not incorporated into standard clinical practice include the following:

p53
Loss of heterozygosity for 18q^[67]
Mutations of deleted in colon cancer gene (DCC)
Epidermal growth factor receptor (EGFR) gene amplification

KRAS mutations, which are present in about 40% of colon adenocarcinomas, affect sensitivity to treatment with biologic agents directed against the epithelial growth factor receptor (EGFR).^[68]The US Food and Drug Administration (FDA) has approved a qualitative real-time polymerase chain reaction (PCR) assay, the therascreen KRAS RGQ PCR Kit, for the detection of specific KRAS mutations in the KRAS oncogene.

Deficient mismatch repair (dMMR), which is associated with high-frequency microsatellite instability (H-MSI), has been shown to be associated with better clinical outcome and lack of benefit from fluorouracil-based adjuvant therapy in patients with stage II or III colon cancer, based on a retrospective analysis of several large randomized trials of adjuvant therapy for colon cancer.^[69]In contrast, those patients with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability do appear to benefit from fluorouracil-based adjuvant therapy.^[70]

Testing for dMMR with H-MSI may become useful for prognosis and treatment planning in patients with resectable colon cancer. Some research also emphasizes the role of immune regulation in the development and in the natural course and prognosis of patients with colorectal cancers.^[71]

For patients aged 60-69 years with selected stage T3 or T4 colorectal cancer, prognostic factor and 5-year relapse-free survival (based on the Mayo Clinic calculator and numbers of lymph nodes analyzed^[72]) are as follows:

T3N0 (11-20 nodes analyzed) – 79%
T3N0 low grade – 73%
T3N0 (≤ 10 lymph nodes examined) – 72%
T3N0 high grade – 65%
T4N0 low grade – 60%
T4N0 high grade – 51%
T3N1 – 49%
T3N2 – 15%

A review of Surveillance, Epidemiology, and End Results (SEER) population-based data on colon cancer by the American Joint Committee on Cancer (AJCC) Hindgut Taskforce found the following:

T1-2N2 cancers have a better prognosis than T3-4N2 cancers
T4bN1 and T4N2 cancers have a similar prognosis
T1-2N1, T2N0, and T3N0 cancers have a similar prognosis
T1-2N2a, T2N0, T3N0 (T1N2a), and T4aN0 (T2N2a) have a similar prognosis
Prognosis for T4a lesions is better than that of T4b by N category
The number of positive nodes affects prognosis

The Taskforce proposed the following revisions of the TN categorization for colon cancer^[73]:

Shift T1-2N2 lesions from IIIC to IIIA/IIIB
Shift T4bN1 from IIIB to IIIC
Subdivide T4/N1 and T4/N2
Revise substaging of stages II/III

Histologic subtype and metastatic patterns

In a retrospective Dutch study of autopsy results from 1675 patients with metastatic colorectal cancer and data from 88 patients with synchronous metastases from the Total Mesorectal Excision (TME) trial, Hugen et al noted that the histologic subtype and the localization of the primary tumor in colorectal cancer has a strong influence on its metastatic pattern.^{[74, 75]}Their findings include the following:

Metastatic disease occurred more frequently and more often in multiple sites, in patients with mucinous adenocarcinoma (MC) (respectively, 33.9% and 58.6% of cases) or signet-ring cell carcinoma (SRCC) (61.2% and 70.7%) compared with those with adenocarcinoma (AC) (27.6% and 49.9%)^{[74, 75]}
Liver metastases occurred more often in patients with AC (73.0%) or MC (52.2%) than in those with SRCC (31.7%)^[75]
Peritoneal metastases occurred more often in patients with SRCC (51.2%) or MC (48.2%) than in those with AC (20.1%)^[75]
Metastases to distant lymph nodes occurred in more SRCC patients (43.9%) than patients with either MC (22.3%) or AC (19.9%)^[75]
Patients with colon cancer had a higher rate of abdominal metastases relative to those with rectal cancer, who had higher rates of extra-abdominal metastases

Treatment & Management

PDQ Adult Treatment Editorial Board. Colon Cancer Treatment–Health Professional Version. National Cancer Institute. Available at http://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq. January 20, 2023; Accessed: January 25, 2023.
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1. 22(1):23-30. [QxMD MEDLINE Link].
Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1. 23(34):8671-8. [QxMD MEDLINE Link].
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3. 350(23):2335-42. [QxMD MEDLINE Link].
Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008 Dec 10. 26(35):5721-7. [QxMD MEDLINE Link].
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1. 319(9):525-32. [QxMD MEDLINE Link].
Chang WH, Cerione RA, Antonyak MA. Extracellular Vesicles and Their Roles in Cancer Progression. Methods Mol Biol. 2021. 2174:143-170. [QxMD MEDLINE Link]. [Full Text].
Zhao X, Yuan C, Wangmo D, Subramanian S. Tumor secreted extracellular vesicles regulate T-cell costimulation and can be manipulated to induce tumor specific T-cell responses. Gastroenterology. 2021 Apr 22. [QxMD MEDLINE Link].
Burn J, Bishop DT, Mecklin JP, Macrae F, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008 Dec 11. 359(24):2567-78. [QxMD MEDLINE Link].
Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 Aug 15. 298(7):754-64. [QxMD MEDLINE Link].
Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011 Nov 10. 343:d6617. [QxMD MEDLINE Link]. [Full Text].
Pala V, Sieri S, Berrino F, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer. 2011 Dec 1. 129(11):2712-9. [QxMD MEDLINE Link].
Tabung FK, Liu L, Wang W, Fung TT, Wu K, Smith-Warner SA, et al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women. JAMA Oncol. 2018 Jan 18. [QxMD MEDLINE Link].
Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009 Jun. 7(6):682-688.e1-5. [QxMD MEDLINE Link].
Cho E, Lee JE, Rimm EB, Fuchs CS, Giovannucci EL. Alcohol consumption and the risk of colon cancer by family history of colorectal cancer. Am J Clin Nutr. 2012 Feb. 95(2):413-9. [QxMD MEDLINE Link]. [Full Text].
Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. Am J Gastroenterol. 2011 Nov. 106(11):1911-21; quiz 1922. [QxMD MEDLINE Link].
Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. 2009 Mar 15. 169(6):657-66. [QxMD MEDLINE Link].
Bailly L, Fabre R, Pradier C, Iannelli A. Colorectal Cancer Risk Following Bariatric Surgery in a Nationwide Study of French Individuals With Obesity. JAMA Surg. 2020 Mar 11. [QxMD MEDLINE Link].
Morikawa T, Kuchiba A, Lochhead P, et al. Prospective Analysis of Body Mass Index, Physical Activity, and Colorectal Cancer Risk Associated with ß-Catenin (CTNNB1) Status. Cancer Res. 2013 Mar 1. 73(5):1600-10. [QxMD MEDLINE Link]. [Full Text].
Zhou E, Wang L, Santiago CN, Nanavati J, Rifkin S, Spence E, et al. Adult-Attained Height and Colorectal Cancer Risk: A Cohort Study, Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2022 Mar 1. [QxMD MEDLINE Link]. [Full Text].
Goncalves MD, Lu C, Tutnauer J, Hartman TE, Hwang SK, Murphy CJ, et al. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019 Mar 22. 363 (6433):1345-1349. [QxMD MEDLINE Link].
Zhang J, Haines C, Watson AJM, Hart AR, Platt MJ, Pardoll DM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study. Gut. 2019 Aug 19. [QxMD MEDLINE Link].
Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. Available at http://seer.cancer.gov/statfacts/html/colorect.html. Accessed: January 25, 2023.
Cancer Facts & Figures 2023. American Cancer Society. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf. Accessed: January 25, 2023.
Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. J Natl Cancer Inst. 28 February 2017. 109:[Full Text].
Kahi CJ, Pohl H, Myers LJ, Mobarek D, Robertson DJ, Imperiale TF. Colonoscopy and Colorectal Cancer Mortality in the Veterans Affairs Health Care System: A Case-Control Study. Ann Intern Med. 2018 Mar 13. [QxMD MEDLINE Link].
World Health Organization, International Agency for Research on Cancer. Colorectal Cancer. Available at http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf. Accessed: January 25, 2023.
Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018 Mar 19. [QxMD MEDLINE Link]. [Full Text].
Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/Black People 2022. CA Cancer J Clin. 2022 May. 72 (3):202-229. [QxMD MEDLINE Link]. [Full Text].
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 Mar 5. [QxMD MEDLINE Link]. [Full Text].
Meester RGS, Mannalithara A, Lansdorp-Vogelaar I, Ladabaum U. Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015. JAMA. 2019 May 21. 321 (19):1933-1934. [QxMD MEDLINE Link].
Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol. 2011 Jun. 103(8):796-800. [QxMD MEDLINE Link].
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep. 230(3):309-18; discussion 318-21. [QxMD MEDLINE Link].
Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2012 Oct 1. [QxMD MEDLINE Link].
Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. Ann Surg Oncol. 2012 Sep 26. [QxMD MEDLINE Link].
Yothers G, Sargent DJ, Wolmark N, et al. Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. J Natl Cancer Inst. 2011 Oct 19. 103(20):1498-1506. [QxMD MEDLINE Link]. [Full Text].
Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012 Jan 1. 30(1):42-52. [QxMD MEDLINE Link].
Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol. 2013 Mar 1. 31(7):876-85. [QxMD MEDLINE Link].
Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011 Apr 27. 305(16):1685-94. [QxMD MEDLINE Link]. [Full Text].
Rothwell PM, Fowkes GR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet. Dec 7/2010; Early online publication. [Full Text].
Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011 Dec 17. 378(9809):2081-7. [QxMD MEDLINE Link]. [Full Text].
Baillargeon J, Kuo YF, Lin YL, et al. Effect of mental disorders on diagnosis, treatment, and survival of older adults with colon cancer. J Am Geriatr Soc. 2011 Jul. 59(7):1268-73. [QxMD MEDLINE Link].
Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: The Seattle Colon Cancer Family Registry. Cancer. 2011 Nov 1. 117(21):4948-57. [QxMD MEDLINE Link]. [Full Text].
Dehal AN, Newton CC, Jacobs EJ, et al. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012 Jan 1. 30(1):53-9. [QxMD MEDLINE Link].
Arhi CS, Ziprin P, Bottle A, Burns EM, Aylin P, Darzi A. Colorectal cancer patients under the age of 50 experience delays in primary care leading to emergency diagnoses: a population-based study. Colorectal Dis. 2019 Aug 6. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021 Mar 1. 116 (3):458-479. [QxMD MEDLINE Link]. [Full Text].
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18. 96(4):261-8. [QxMD MEDLINE Link]. [Full Text].
Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management. J Natl Cancer Inst. 2011 Apr 20. 103(8):689-97. [QxMD MEDLINE Link].
When Should You Start Getting Screened for Colorectal Cancer?. American Cancer Society. Available at https://www.cancer.org/latest-news/american-cancer-society-updates-colorectal-cancer-screening-guideline.html?utm_campaign&. February 4, 2021; Accessed: January 25, 2023.
Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg. 2012 Sep 21. [QxMD MEDLINE Link].
Holme O, et al for the NORCCAP Study Group. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Ann Intern Med. 24 April 2018. [Full Text].
Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011 Dec 7. 103(23):1741-51. [QxMD MEDLINE Link].
Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016 Jan 26. [QxMD MEDLINE Link]. [Full Text].
Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA. 2017 Apr 25. 317 (16):1631-1641. [QxMD MEDLINE Link].
Gandhi S, Narula N, Mosleh W, Marshall JK, Farkouh M. Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy. Aliment Pharmacol Ther. 2013 May. 37(10):947-52. [QxMD MEDLINE Link].
Nelson R. FDA Approves Cologuard for Colorectal Cancer Screening. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829757. August 11, 2014; Accessed: January 30, 2018.
Brooks M. FDA Clears First Blood-Based Colorectal Cancer Screening Test. Medscape Medical News. Available at https://www.medscape.com/viewarticle/861942. April 14, 2016; Accessed: January 30, 2018.
[Guideline] Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008 May-Jun. 58(3):130-60. [QxMD MEDLINE Link].
Karsenti D, Tharsis G, Burtin P, Venezia F, Tordjman G, Gillet A, et al. Adenoma and advanced neoplasia detection rates increase from 45 years of age. World J Gastroenterol. 2019 Jan 28. 25 (4):447-456. [QxMD MEDLINE Link]. [Full Text].
Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial. Arch Intern Med. 2011 May 23. 171(10):906-12. [QxMD MEDLINE Link].
[Guideline] Johnson DA, Barkun AN, Cohen LB, Dominitz JA, Kaltenbach T, Martel M, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 Oct. 109 (10):1528-45. [QxMD MEDLINE Link]. [Full Text].
Given Imaging Receives FDA Clearance for PillCam® COLON in Patients Following Incomplete Colonoscopy. Med Device Online. Available at https://www.meddeviceonline.com/doc/given-imaging-fda-pillcam-colon-incomplete-colonoscopy-0001. February 3, 2014; Accessed: January 25, 2023.
Spada C, De Vincentis F, Cesaro P, Hassan C, Riccioni ME, Minelli Grazioli L, et al. Accuracy and safety of second-generation PillCam COLON capsule for colorectal polyp detection. Therap Adv Gastroenterol. 2012 May. 5(3):173-8. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et al. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020 Feb 5. 143(3):844-57. [QxMD MEDLINE Link].
[Guideline] Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 May 1. 35 (13):1453-1486. [QxMD MEDLINE Link]. [Full Text].
American Joint Committee on Cancer. Colon and Rectum. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, et al, eds. AJCC Cancer staging manual. 8th ed. New York: Springer; 2017.
Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer. 2007 May 2. 7:72. [QxMD MEDLINE Link].
Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection. J Clin Oncol. 2009 Jan 5. [QxMD MEDLINE Link].
Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10. 28 (20):3219-26. [QxMD MEDLINE Link]. [Full Text].
Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 Jul 17. 349(3):247-57. [QxMD MEDLINE Link].
Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011 Feb 20. 29(6):610-8. [QxMD MEDLINE Link].
Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003 Aug 1. 21(15):2912-9. [QxMD MEDLINE Link].
Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10. 28(2):264-71. [QxMD MEDLINE Link]. [Full Text].
Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014 Mar. 25(3):651-7. [QxMD MEDLINE Link].
Boggs W. Histology influences colorectal cancer metastatic pattern. Reuters Health Information. March 11, 2014. [Full Text].
[Guideline] Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Dec 22. 22(16):JCO2102538. [QxMD MEDLINE Link]. [Full Text].
Boller AM, Nelson H. Colon and rectal cancer: laparoscopic or open?. Clin Cancer Res. 2007 Nov 15. 13(22 Pt 2):6894s-6s. [QxMD MEDLINE Link].
Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart RW Jr. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg. 2007 Oct. 246(4):655-62; discussion 662-4. [QxMD MEDLINE Link].
Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007 Jul 20. 25(21):3061-8. [QxMD MEDLINE Link].
Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev. 2008 Apr 16. CD003432. [QxMD MEDLINE Link].
Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg. 2008 Jul. 248(1):1-7. [QxMD MEDLINE Link].
Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005 Jul. 6(7):477-84. [QxMD MEDLINE Link].
Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG. Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. J Clin Oncol. 2009 Jun 1. [QxMD MEDLINE Link].
Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, et al. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol. 2012 Feb. 19(2):379-83. [QxMD MEDLINE Link].
Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011 Nov. 18(12):3252-60. [QxMD MEDLINE Link]. [Full Text].
Di Benedetto F, Berretta M, D'Amico G, et al. Liver resection for colorectal metastases in older adults: a paired matched analysis. J Am Geriatr Soc. 2011 Dec. 59(12):2282-90. [QxMD MEDLINE Link].
Brouquet A, Overman MJ, Kopetz S, et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer. 2011 Oct 1. 117(19):4484-92. [QxMD MEDLINE Link]. [Full Text].
House MG, Kemeny NE, Gonen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011 Dec. 254(6):851-6. [QxMD MEDLINE Link].
van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol. 2011 Apr. 12(4):344-52. [QxMD MEDLINE Link].
Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb 20. 27(6):872-7. [QxMD MEDLINE Link].
Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012 May. 23 (5):1190-1197. [QxMD MEDLINE Link]. [Full Text].
Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015 Nov 10. 33 (32):3733-40. [QxMD MEDLINE Link]. [Full Text].
van Erning FN, Creemers GJ, De Hingh IH, Loosveld OJ, Goey SH, Lemmens VE. Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older. Ann Oncol. 2013 Aug 8. [QxMD MEDLINE Link].
André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013. 9:261-269. [QxMD MEDLINE Link]. [Full Text].
Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Jun 1. 37 (16):1436-1447. [QxMD MEDLINE Link]. [Full Text].
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Available at https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Version 2.2022 — October 27, 2022; Accessed: January 25, 2023.
Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15. 370(9604):2020-9. [QxMD MEDLINE Link].
O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011 Sep 1. 29(25):3381-8. [QxMD MEDLINE Link]. [Full Text].
Petrelli F, Labianca R, Zaniboni A, et al. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. JAMA Oncol. 2020 Feb 13. [QxMD MEDLINE Link].
Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10. 27(17):2848-54. [QxMD MEDLINE Link]. [Full Text].
Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011 May 21. 377(9779):1749-59. [QxMD MEDLINE Link].
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14. 372 (20):1909-19. [QxMD MEDLINE Link].
Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004. 20 (4-5):199-206. [QxMD MEDLINE Link]. [Full Text].
Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013 Jan. 14(1):29-37. [QxMD MEDLINE Link].
Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009 Jan 10. 27(2):199-205. [QxMD MEDLINE Link].
Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017 Sep 1. 28 (9):2128-2134. [QxMD MEDLINE Link]. [Full Text].
Tebbutt NC, Murphy F, Zannino D, et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol. 2011 Aug. 22(8):1834-8. [QxMD MEDLINE Link].
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011 Jan 1. 29(1):11-6. [QxMD MEDLINE Link].
Stark, Angela. FDA approves first biosimilar for the treatment of cancer. FDA News Release. 09/14/2017. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576112.htm.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22. 351(4):337-45. [QxMD MEDLINE Link].
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011 May 20. 29(15):2011-9. [QxMD MEDLINE Link].
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2. 360(14):1408-17. [QxMD MEDLINE Link]. [Full Text].
Lin AY, Buckley NS, Lu AT, et al. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin Colorectal Cancer. 2011 Mar 1. 10(1):63-9. [QxMD MEDLINE Link].
Chustecka Z. FDA Approves Panitumumab for Use With FOLFOX in mCRC. Medscape Medical News. Available at http://www.medscape.com/viewarticle/825699. Accessed: June 2, 2014.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1. 28(31):4697-705. [QxMD MEDLINE Link].
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Nov 1. 28(31):4706-13. [QxMD MEDLINE Link].
Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May. 15(6):569-79. [QxMD MEDLINE Link].
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10. 27(5):672-80. [QxMD MEDLINE Link].
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10. 27(5):663-71. [QxMD MEDLINE Link].
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12. 369(11):1023-34. [QxMD MEDLINE Link].
Kim TW, Elme A, Kusic Z, Park JO, Udrea AA, Kim SY, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016 Nov 8. 115 (10):1206-1214. [QxMD MEDLINE Link]. [Full Text].
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 Apr 10. [QxMD MEDLINE Link].
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Jul 19. [QxMD MEDLINE Link]. [Full Text].
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Mar 10. 36 (8):773-779. [QxMD MEDLINE Link].
Opdivo (nivolumab) [package insert]. Bristol-Myers Squibb Company: Princeton, NJ 08543 USA. 7/2017. Available at [Full Text].
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25. 372 (26):2509-20. [QxMD MEDLINE Link]. [Full Text].
Stivarga (regorafenib) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. September 2012. Available at [Full Text].
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26. 381 (9863):303-12. [QxMD MEDLINE Link].
Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics. 2014. 8:13-25. [QxMD MEDLINE Link]. [Full Text].
Van Cutsem E, et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun. 11 (3):383-400. [QxMD MEDLINE Link]. [Full Text].
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1. 30(28):3499-506. [QxMD MEDLINE Link].
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. U.S. Food & Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor. November 26, 2018; Accessed: June 5, 2019.
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24. 381 (17):1632-1643. [QxMD MEDLINE Link].
Davenport L. Updated BEACON: Doublet as Good as Triplet in Metastatic CRC. Medscape Medical News. Available at https://www.medscape.com/viewarticle/931555. June 2, 2020; Accessed: February 11, 2021.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Apr 20. [QxMD MEDLINE Link]. [Full Text].
Otto MA. Tucatinib Plus Trastuzumab Approved for HER2+ Colorectal Cancer. Medscape Medical News. Available at https://www.medscape.com/viewarticle/987242. January 20, 2023; Accessed: January 240, 2023.
Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010 Aug 10. 28(23):3687-94. [QxMD MEDLINE Link].
Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS, et al. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol. 2017 Nov 2. [QxMD MEDLINE Link]. [Full Text].
Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, Zhang S, et al. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Netw Open. 2022 Feb 1. 5 (2):e220145. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2013 Nov 12. [QxMD MEDLINE Link].
[Guideline] Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct. 24 Suppl 6:vi64-72. [QxMD MEDLINE Link].
Kirkegaard H, Johnsen NF, Christensen J, Frederiksen K, Overvad K, Tjonneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ. 2010 Oct 26. 341:c5504. [QxMD MEDLINE Link]. [Full Text].
Kim J, Boushey CJ, Wilkens LR, Haiman CA, Le Marchand L, Park SY. Plant-based dietary patterns defined by a priori indices and colorectal cancer risk by sex and race/ethnicity: the Multiethnic Cohort Study. BMC Med. 2022 Nov 29. 20 (1):430. [QxMD MEDLINE Link]. [Full Text].
Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 1. 24(22):3535-41. [QxMD MEDLINE Link].
Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med. 2015 Oct 15. 373 (16):1519-30. [QxMD MEDLINE Link]. [Full Text].
Barry EL, Peacock JL, Rees JR, Bostick RM, Robertson DJ, Bresalier RS, et al. Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial. JAMA Oncol. 2016 Dec 15. [QxMD MEDLINE Link].
McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, et al. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. J Natl Cancer Inst. 2018 Jun 14. [QxMD MEDLINE Link].
Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011 Jun. 106(6):1135-46. [QxMD MEDLINE Link].
Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007 May 12. 369(9573):1603-13. [QxMD MEDLINE Link].
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb 18. 101(4):256-66. [QxMD MEDLINE Link].
Zhang X, Smith-Warner SA, Chan AT, et al. Aspirin Use, Body Mass Index, Physical Activity, Plasma C-Peptide, and Colon Cancer Risk in US Health Professionals. Am J Epidemiol. 2011 Aug 15. 174(4):459-67. [QxMD MEDLINE Link].
Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013 Jun 26. 309(24):2563-71. [QxMD MEDLINE Link].
Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial. Ann Intern Med. 2013 Jul 16. 159(2):77-85. [QxMD MEDLINE Link].
Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa). 2008 Jun. 1(1):32-8. [QxMD MEDLINE Link].
[Guideline] American Cancer Society Guideline for Colorectal Cancer Screening. American Cancer Society. Available at https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html. May 30, 2018; Accessed: May 25, 2019.
[Guideline] US Preventive Services Task Force., Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 May 18. 325 (19):1965-1977. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Qaseem A, Crandall CJ, Mustafa RA, Hicks LA, Wilt TJ, Clinical Guidelines Committee of the American College of Physicians., et al. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. Ann Intern Med. 2019 Nov 5. 171 (9):643-654. [QxMD MEDLINE Link]. [Full Text].
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. NCCN. Available at http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Version 3.2022 — September 30, 2022; Accessed: January 25, 2023.
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Colorectal. NCCN. Available at http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Version 2.2022 — December 7, 2022; Accessed: January 25, 2023.
[Guideline] Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct. 31 (10):1291-1305. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Oct 1. 30 (10):1558-1571. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Rubenstein JH, Enns R, Heidelbaugh J, Barkun A, Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015 Sep. 149 (3):777-82; quiz e16-7. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2013 Oct. 24 Suppl 6:vi73-80. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015 Jan 10. 33 (2):209-17. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 Feb. 110 (2):223-62; quiz 263. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Rutter MD, East J, Rees CJ, Cripps N, Docherty J, Dolwani S, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut. 2020 Feb. 69 (2):201-223. [QxMD MEDLINE Link]. [Full Text].
Church J, Simmang C, Standards Task Force, American Society of Colon and Rectal Surgeons, Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of The American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum. 2003 Aug. 46 (8):1001-12. [QxMD MEDLINE Link].
Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022 Feb 1. 65 (2):148-177. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2015 Aug. 58 (8):713-25. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar. 150 (3):758-768.e11. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10. 34 (2):179-85. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug. 27 (8):1386-422. [QxMD MEDLINE Link]. [Full Text].
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15. 22(2):229-37. [QxMD MEDLINE Link].
Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008 Dec 20. 26(36):5910-7. [QxMD MEDLINE Link].
Sehgal R, Lembersky BC, Rajasenan KK, et al. A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clin Colorectal Cancer. 2011 Jun. 10(2):117-20. [QxMD MEDLINE Link].
Rozyltrek (entrectinib) [package insert]. South San Francisco, CA: Genentech USA, Inc. August, 2019. Available at [Full Text].

Media Gallery

Standard colectomies for adenocarcinoma of the colon.

of 1

Table 1. TNM Classification for Colon Cancer

Primary tumor (T)
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ: intraepithelial or intramucosal carcinoma (involvement of lamina propria with no extension through the muscularis mucosa)
T1	Tumor invades submucosa (through the muscularis mucosa but not into the muscularis propria)
T2	Tumor invades muscularis propria
T3	Tumor invades through the muscularis propria into the pericolorectal tissues
T4	Tumor invades the visceral peritoneum or invades or adheres to adjacent organ or structure
T4a	Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum)
T4b	Tumor directly invades or is adherent to other organs or structures
T Suffix	Definition
(m)	Select if synchronous primary tumors are found in a single organ
Definition of Regional lymph nodes (N)
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in 1-3 regional lymph nodes (tumor in lymph nodes measuring ≥0.2 mm) or any number of tumor deposits are present and all identifiable nodes are negative
N1a	Metastasis in 1 regional lymph node
N1b	Metastasis in 2-3 regional lymph nodes
N1c	Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized, pericolic, or perirectal/mesorectal tissues without regional nodal metastasis
N2	Metastasis in 4 or more lymph nodes
N2a	Metastasis in 4-6 regional lymph nodes
N2b	Metastasis in 7 or more regional lymph nodes
N Suffix	Definition
(sn)	Select if regional lymph node metastasis identified by sentinel lymph node biopsy only
(f)	Select if regional lymph node metastasis identified by fine needle aspiration or core needle biopsy
Definition of Distant metastasis (M) The terms pM0 and Mx are not valid categories in the TNM system. Assignment of the M category for clinical classification may be cM0, cM1 or pM1. Any of the categories (cM0, CM1 or pM1) may be used with pathological stage grouping.
M Category	M Criteria
cM0	No distant metastasis by imaging or other studies, no evidence of tumor in distant sites or organs. (This category is not assigned by pathologists.)
cM1	Metastasis to one or more distant sites or organs or peritoneal metastasis is identified
cM1a	Metastasis confined to 1 organ or site is identified without peritoneal metastasis
cM1b	Metastasis to two or more sites or organs is identified without peritoneal metastasis
M1c	Metastasis to the peritoneal surface alone or with other site or organ metastases
pM1	Metastasis to one or more distant sites or organs or peritoneal metastasis is identified and microscopically confirmed
pM1a	Metastasis to one site or organ is identified without peritoneal metastasis and microscopically confirmed
pM1b	Metastasis to two or more sites or organs is identified without peritoneal metastasis and microscopically confirmed.
pM1c	Metastasis to the peritoneal surface is identified alone or with other site or organ metastasis and microscopically confirmed

Table 2. Anatomic stage/prognostic groups

0	Tis	N0	M0
I	T1	N0	M0
	T2	N0	M0
IIA	T3	N0	M0
IIB	T4a	N0	M0
IIC	T4b	N0	M0
IIIA	T1-T2	N1/N1c	M0
	T1	N2a	M0
IIIB	T3-T4a	N1/N1c	M0
	T2-T3	N2a	M0
	T1-T2	N2b	M0
IIIC	T4a	N2a	M0
	T3-T4a	N2b	M0
	T4b	N1-N2	M0
IVA	Any T	Any N	M1a
IVB IVC	Any T Any T	Any N Any T	M1b M1c

Table 2. Surveillance recommendations for stage II and III colon cancer

Parameter	Organization
Parameter	ESMO [JSMO](2013)	ASCO (2013)	NCCN (2016)
History and physical exam	Every 3-6 mo for 3 y, then every 6 -12 mo at 4 and 5 y	Every 3-6 mo for 3 y, then every 6 mo to 5 y	Every 3-6 mo for 2 y, then every 6 mo to 5 y
CEA	Every 3-6 mo for 3 y, then every 6 -12 mo at 4 and 5 y	Every 3 mo for 3 y*	Every 3-6 mo for 2 y, then every 6 mo to 5 y
Chest CT*	Every 6-12 mo for first 3 y	Every 1 y for 3 y	Every 1 y for 5 y
Colonoscopy**	At y 1 after surgery, and every 3-5 y thereafter	At 1 y, then every 5 y, dictated by the findings on the previous colonoscopy	At 1 y, 3 y, then every 5 y if negative
Abdominal CT*	Every 6-12 mo for first 3 y	Every 1 y for 3 y	Every 6-12 mo for up to 5 y; scans to include chest and pelvis
ESMO = European Society of Medical Oncology; JSMO = Japanese Society of Medical Oncology; ASCO = American Society of Clinical Oncology; NCCN = National Comprehensive Cancer Network; CEA = carcinoembryonic antigen; CT = computed tomography * For patients at high risk for recurrence (eg, lymphatic or venous invasion, or poorly differentiated tumors). **Colonoscopy should be performed 3-6 mo postoperatively if preoperative colonoscopy was not done, due to an obstructing lesion; otherwise, colonoscopy in 1 y; if abnormal, repeat in 1 year; if no advanced adenoma (ie, villous polyp, polyp > 1 cm, or high-grade dysplasia), repeat in 3 y, then every 5 y.

Table 1.

Parameter	Organization
Parameter	ESMO (2013)^[141]	ASCO (2013)^[140]	NCCN (2022)^[96]	ASCRS (2015)^[169]
History and physical exam	Every 3-6 mo for 3 y, then every 6 -12 mo at 4 and 5 y	Every 3-6 mo for 3 y, then every 6 mo to 5 y	Every 3-6 mo for 2 y, then every 6 mo to 5 y	Every 3-6 mo for 2 y, then every 6 mo to 5 y
CEA	Every 3-6 mo for 3 y, then every 6 -12 mo at 4 and 5 y	Every 3 mo for 3 y*	Every 3-6 mo for 2 y, then every 6 mo to 5 y	Every 3-6 mo for 2 y, then every 6 mo to 5 y
Chest CT*	Every 6-12 mo for first 3 y	Every 1 y for 3 y	Every 6-12 mo for 5 y	Every 1 y for 5 y
Colonoscopy**	At y 1 after surgery, and every 3-5 y thereafter	At 1 y, then every 5 y, dictated by the findings on the previous colonoscopy	At 1 y; if advanced adenoma, repeat in 1 y; if no advanced adenoma, repeat in 3 y, then every 5 y	At y 1 after surgery, and every 3-5 y dictated by the findings on the first postoperative examination
Abdominal CT*	Every 6-12 mo for first 3 y	Every 1 y for 3 y	Every 6-12 mo for 5 y; scans to include pelvis	Every 1 y for 5 y
ESMO = European Society of Medical Oncology; ASCO = American Society of Clinical Oncology; NCCN = National Comprehensive Cancer Network; American Society of Colon and Rectal Surgeons = ASCRS CEA = carcinoembryonic antigen; CT = computed tomography * For patients at high risk for recurrence (eg, lymphatic or venous invasion, or poorly differentiated tumors). **Colonoscopy should be performed 3-6 mo postoperatively if preoperative colonoscopy was not done, due to an obstructing lesion; otherwise, colonoscopy in 1 y; if abnormal, repeat in 1 year; if no advanced adenoma (ie, villous polyp, polyp >1 cm, or high-grade dysplasia), repeat in 3 y, then every 5 y.